NCT02611505View on ClinicalTrials.gov

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

February 27, 2017

Study Completion Date

February 27, 2017

Conditions

Hepatic ImpairmentNormal Hepatic Function

Interventions

DRUG

Esketamine

Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.

Trial Locations (1)

Unknown

Knoxville

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02611505 - A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine | Biotech Hunter | Biotech Hunter